144 related articles for article (PubMed ID: 5286449)
1. Leukemia and related disorders.
Anderson RE
Hum Pathol; 1971 Dec; 2(4):505-14. PubMed ID: 5286449
[No Abstract] [Full Text] [Related]
2. [Myeloproliferative syndrome, myelofibrosis and erythrocytosis. A retrospective study].
Retief FP; Du P Heyns A
S Afr Med J; 1974 Dec; 48(59):2429-35. PubMed ID: 4532812
[No Abstract] [Full Text] [Related]
3. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients.
Cervantes F; Tassies D; Salgado C; Rovira M; Pereira A; Rozman C
Acta Haematol; 1991; 85(3):124-7. PubMed ID: 2042444
[TBL] [Abstract][Full Text] [Related]
4. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis.
Kutti J; Ridell B
Pathol Biol (Paris); 2001 Mar; 49(2):164-6. PubMed ID: 11317963
[TBL] [Abstract][Full Text] [Related]
6. The role of genotypes that modify the toxicity of chemical mutagens in the risk for myeloproliferative neoplasms.
Gross-Davis CA; Heavner K; Frank AL; Newschaffer C; Klotz J; Santella RM; Burstyn I
Int J Environ Res Public Health; 2015 Feb; 12(3):2465-85. PubMed ID: 25719551
[TBL] [Abstract][Full Text] [Related]
7. [MYELOPROLIFERATIVE SYNDROMES].
PIRESWDA F
Folha Med; 1964 Apr; 48():195-201. PubMed ID: 14271209
[No Abstract] [Full Text] [Related]
8. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
9. [Myeloproliferative disorders].
Binder D; Fehr J
Ther Umsch; 2004 Feb; 61(2):131-42. PubMed ID: 15018396
[TBL] [Abstract][Full Text] [Related]
10. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
Deadmond MA; Smith-Gagen JA
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
[TBL] [Abstract][Full Text] [Related]
11. How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
Titmarsh GJ; Duncombe AS; McMullin MF; O'Rorke M; Mesa R; De Vocht F; Horan S; Fritschi L; Clarke M; Anderson LA
Am J Hematol; 2014 Jun; 89(6):581-7. PubMed ID: 24971434
[TBL] [Abstract][Full Text] [Related]
12. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.
Verstovsek S; Yu J; Scherber RM; Verma S; Dieyi C; Chen CC; Parasuraman S
Leuk Lymphoma; 2022 Mar; 63(3):694-702. PubMed ID: 34689695
[TBL] [Abstract][Full Text] [Related]
13. The spectrum of myeloproliferative disorders.
Gilbert HS
Med Clin North Am; 1973 Mar; 57(2):355-93. PubMed ID: 4570933
[No Abstract] [Full Text] [Related]
14. Leukemic transformation in patients with myeloproliferative neoplasms: a population-based retrospective study.
Shrestha R; Giri S; Armitage JO; Bhatt VR
Future Oncol; 2017 Jun; 13(14):1239-1246. PubMed ID: 28589759
[TBL] [Abstract][Full Text] [Related]
15. An addition to geographic hematology: chronic myeloproliferative diseases are infrequent in Mexican Mestizos.
Ruiz-Argüelles GJ; López-Martínez B; Lobato-Mendizábal E; Ruiz-Delgado GJ
Int J Hematol; 2002 Jun; 75(5):499-502. PubMed ID: 12095150
[TBL] [Abstract][Full Text] [Related]
16. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.
Greenberg PL
Clin Haematol; 1986 Nov; 15(4):973-93. PubMed ID: 3552351
[No Abstract] [Full Text] [Related]
17. An association of myeloproliferative neoplasms and obliterative portal venopathy.
Mayer JE; Schiano TD; Fiel MI; Hoffman R; Mascarenhas JO
Dig Dis Sci; 2014 Jul; 59(7):1638-41. PubMed ID: 24474573
[No Abstract] [Full Text] [Related]
18. Contemporary approach to essential thrombocythemia and polycythemia vera.
Aruch D; Mascarenhas J
Curr Opin Hematol; 2016 Mar; 23(2):150-60. PubMed ID: 26717193
[TBL] [Abstract][Full Text] [Related]
19. A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series.
Smith CJ; Thomas JW; Ruan G; Hyun MC; Bansal R; McLaughlin N; Pardanani A; Gangat N; Go RS; Szuber N; Goyal G; Shah MV; Tefferi A
Am J Hematol; 2021 Dec; 96(12):E464-E468. PubMed ID: 34661932
[No Abstract] [Full Text] [Related]
20. Clinical predictors of outcome in MPN.
Passamonti F; Maffioli M; Merli M; Ferrario A; Caramazza D
Hematol Oncol Clin North Am; 2012 Oct; 26(5):1101-16. PubMed ID: 23009940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
